Journal article
Long‐term clearance of hepatitis C virus following interferon α‐2b or peginterferon α‐2b, alone or in combination with ribavirin
Journal of viral hepatitis, Vol.20(8), pp.524-529
08/2013
DOI: 10.1111/jvh.12074
PMID: 23808990
Abstract
Summary
Sustained virologic response (SVR) is the standard measure for evaluating response to therapy in patients with chronic hepatitis C (CHC). The aim of this study was to prospectively assess the durability of SVR in the pivotal studies of peginterferon (PEG‐IFN) α‐2b or IFN α‐2b. We conducted two phase 3b long‐term follow‐up studies of patients previously treated for CHC in eight prospective randomized studies of IFN α‐2b and/or PEG‐IFN α‐2b. Patients who achieved SVR [undetectable hepatitis C virus (HCV) RNA 24 weeks after completion of treatment] were eligible for inclusion in these follow‐up studies. In total, 636 patients with SVR following treatment with IFN α‐2b and 366 with SVR following treatment with PEG‐IFN α‐2b were enrolled. Definite relapse (quantifiable serum HCV RNA with no subsequent undetectable HCV RNA) was reported in six patients treated with IFN α‐2b and three patients treated with PEG‐IFN α‐2b. Based on these relapses, the point estimate for the likelihood of maintaining response after 5 years was 99.2% [95% confidence interval (CI), 98.1–99.7%] for IFN α‐2b and 99.4% (95% CI, 97.7–99.9%) for PEG‐IFN α‐2b. Successful treatment of hepatitis C with PEG‐IFN α‐2b or IFN α‐2b leads to clinical cure of hepatitis C in the vast majority of cases.
Details
- Title: Subtitle
- Long‐term clearance of hepatitis C virus following interferon α‐2b or peginterferon α‐2b, alone or in combination with ribavirin
- Creators
- M. P Manns - Hannover Medical SchoolP. J Pockros - The Scripps ClinicG Norkrans - Sahlgrenska University HospitalC. I Smith - University of MinnesotaT. R Morgan - VA Long Beach Healthcare SystemD Häussinger - Heinrich Heine UniversitätM. L Shiffman - Bon Secours Health SystemS. J Hadziyannis - Henry Dunant HospitalW. N Schmidt - University of IowaI. M Jacobson - Weill Cornell Medical CollegeR Bárcena - Hospital Ramon y CajalE. R Schiff - University of Miami Miller School of MedicineO. S Shaikh - University of Pittsburgh School of MedicineB Bacon - Saint Louis University School of MedicineP Marcellin - Beaujon HospitalR Esteban‐Mur - Hospital Universitari Valle HebronW Deng - a subsidiary of Merck & Co., IncT Poynard - Hôpital La Pitié SalpêtrièreL. D Pedicone - a subsidiary of Merck & Co., IncC. A Brass - a subsidiary of Merck & Co., IncJ. K Albrecht - a subsidiary of Merck & Co., IncS. C Gordon - Henry Ford Health Systems
- Resource Type
- Journal article
- Publication Details
- Journal of viral hepatitis, Vol.20(8), pp.524-529
- DOI
- 10.1111/jvh.12074
- PMID
- 23808990
- ISSN
- 1352-0504
- eISSN
- 1365-2893
- Number of pages
- 6
- Grant note
- Merck & Co., Inc.
- Language
- English
- Date published
- 08/2013
- Academic Unit
- Gastroenterology and Hepatology; Internal Medicine
- Record Identifier
- 9984094726302771
Metrics
16 Record Views